Advanced Screening for Alzheimer’s with AI

Pre-symptomatic risk assessment and early disease signal detection of Alzheimer’s using pre-existing patient data.

Learn More

Transforming Alzheimer's Screening

ALZAI is the first AI-driven Alzheimer’s Disease risk screening platform using non-invasive, low-cost, pre-existing data, providing early detection, and improving patient outcomes.

Risk Assessment & Early Detection

Identifies Alzheimer’s disease risk up to 10 years before symptoms appear, enabling earlier intervention and better patient outcomes.

Proven Results with over 500,000 patients

Proven effectiveness with over 500,000 diverse patients, demonstrating unparalleled and reliable screening capabilities.

Accessible for everyone, everywhere

Delivering Non-Invasive, low-cost screening solution enabling Alzheimer’s screening for entire patient populations.

Seamless Screening Experience

Built on a use -friendly, easily integrated platform for healthcare providers, clinical researchers, and stakeholders to engage ALZAI Screening.

Our Key Stakeholders

ALZAI serves diverse healthcare stakeholders, offering tailored benefits to each group,with a primary focus on clinical trials companies.

Save cost and time through pre-screening subjects with ALZAI. Identifying quality candidates early, lowering screen-failure rates and significantly accelerating recruitment.

Enhance patient care by integrating seamless Alzheimer’s risk screening into regular primary care delivery, improving patient outcomes.

Public or Private, ALZAI enables substantial gains by enabling risk-mitigation, disease prevention, care optimization through risk-flagging and early detection.

Gain early insight into Alzheimer’s disease risk, enabling proactive healthcare management and lifestyle changes promoting longevity.

Addressing the Alzheimer's Challenge with ALZAI

ALZAI addresses the significant unmet need in Alzheimer’s Disease (AD): Risk Screening. Only 17% of mild cognitive impairment (MCI) and mild AD cases are identified today due to the lack of screening and complete reliance on physician suspicion. By leveraging AI on existing patient data ALZAI can increase detection rates of mild MCI and AD to 80%+. With our patented non-invasive screening solution, ALZAI flags at-risk patients enabling earlier identification and diagnosis of mild disease for earlier intervention, and identification of high-risk pre-symptomatic patients for preventative care. ALZAI is transformational support for better clinical decision-making.